Skip to main content

Carlos A. Alemany, MD

Carlos A. Alemany, MD

Medical Director (Clinical Research), Medical Oncologist

Cancer

Carlos Alemany

Overview

Carlos Alemany, MD is a board-certified hematology and oncology physician in Orlando. Dr. Alemany earned his medical degree from Ponce School of Medicine in Ponce, Puerto Rico. He went on to complete a residency at the Cleveland Clinic Foundation in Cleveland, OH, staying there to pursue a fellowship as well. Dr. Alemany specializes in breast cancer and genitourinary malignancies. As an established member of the medical community, Dr. Alemany has authored and co-authored multiple articles in peer-reviewed medical journals on the topics of breast and genitourinary cancer. In addition to that, he has also authored many other articles related to lung cancer, lymphoma, anemia, multiple myeloma, colon cancer and novel chemotherapy agents. An award-winning physician, Dr. Alemany has been recognized as one of the Best Doctors in America every year since 2009 by Best Doctors, Inc, and the Orlando Magazine for his dedication to research and superior patient health. He is an associate professor at the University of Central Florida, and he is fluent in both English and Spanish.

Articles

Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study

ANNALS OF ONCOLOGY

2022

Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood

PloS one

2022

SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

ANNALS OF ONCOLOGY

2020

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

CLINICAL BREAST CANCER

2019

A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer

CANCER RESEARCH

2019

Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval

JOURNAL OF ONCOLOGY PRACTICE

2015

Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor

CASE REPORTS IN ENDOCRINOLOGY

2015

Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care

JOURNAL OF ONCOLOGY PRACTICE

2015

Etirinotecan Pegol: Development of a Novel Conjugated Topoisomerase I Inhibitor

CURRENT ONCOLOGY REPORTS

2014

Florida Initiative for Quality Cancer Care: Improvements in Breast Cancer Quality Indicators During a 3-Year Interval

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

2014

Education & Training

Education

Ponce School of Medicine, Ponce, Puerto Rico

Residency

The Cleveland Clinic Foundation, Cleveland, OH

Fellowship

The Cleveland Clinic Foundation, Cleveland, OH

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT04071457

Phase III Study of Daratumumab/rHuPH20 (NSC - 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Icon for trial | S1803 Phase III Study of Daratumumab/rHuPH20 (NSC - 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMA

This study is being done to answer the following questions: (1) Will adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help myeloma patients survive longer?; and ...

NCT04586231

An Open-label, Randomized, Phase 2 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Icon for trial | MK-6482-011 An Open-label, Randomized, Phase 2 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L

This study is currently enrolling.

This trial is being done to test MK-6482 + lenvatinib in people with a type of kidney cancer called advanced clear cell Renal Cell Carcinoma (ccRCC). MK-6482 is still being researched and has not been approved to use alone or w ...

NCT04529772

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R CHOP) in Subjects ≤70 Years with Previously Untreated Non-Germinal Center Diffuse Large B Cell Lymphoma

Icon for trial | ACE-LY-312 (ESCALADE) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R CHOP) in Subjects ≤70 Years with Previously Untreated Non-

This study is currently enrolling.

This study is being done to understand whether patients with a type of DLBCL known as non-germinal center diffuse large B-cell lymphoma (non-GCB DLBCL) will benefit from the addition of acalabrutinib to standard R-CHOP versus R ...

NCT05508906

A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer

Icon for trial | OP-1250-003 A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer

This study is currently enrolling.

Participants will be invited to take part in this clinical research study if they have been treated for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 negative (HER2)-negative breast cancer and have ...

NCT06191796

XL092-009 A Phase 1b/2 Dose-Finding And Expansion Study Evaluating The Safety And Efficacy Of Xl092 Combined With Either AB521 OR AB521 Plus Nivolumab In Subjects With Advanced Clear Cell Renal Cell Carcinoma Or Other Advanced Solid Tumors

Icon for trial | XL092-009 XL092-009  A Phase 1b/2 Dose-Finding And Expansion Study Evaluating The Safety And Efficacy Of Xl092 Combined With Either AB521 OR AB521 Plus Nivolumab In Subjects With Advanced Clear Cell Renal Cell Carcinoma Or Other Advanced Solid Tumors

This study is currently enrolling.

To determine the recommended doses (RDs) of zanzalintinib and AB521 when administered in combination (doublet) in subjects with advanced solid tumors, and in combination plus nivolumab (triplet) in subjects with advanced ccRCC ...